Blood Tests and Tumor Markers in Cancer Diagnosis

Blood-based laboratory tests occupy a central role in the detection, staging, and monitoring of cancer, with tumor markers forming one of the most clinically consequential categories within that landscape. This page covers how tumor markers work, which markers are associated with specific cancer types, the regulatory and clinical standards that govern their use, and the boundaries of what blood tests can and cannot determine. Understanding these boundaries is essential because elevated markers alone rarely confirm a diagnosis — context, imaging, and pathology reports all contribute to a complete clinical picture.

Definition and scope

A tumor marker is a substance — typically a protein, hormone, enzyme, or fragment of genetic material — that is produced by cancer cells or by the body in response to malignancy, and that can be measured in blood, urine, or tissue. The U.S. Food and Drug Administration (FDA) regulates the approval of tumor marker assays as in vitro diagnostic devices under 21 CFR Part 809 (FDA, In Vitro Diagnostics).

The scope of blood-based cancer testing extends beyond tumor markers to include:

• Complete blood count (CBC): Detects abnormalities in red blood cells, white blood cells, and platelets that may indicate leukemia or lymphoma.
• Comprehensive metabolic panel (CMP): Assesses liver and kidney function, which can reflect tumor burden or treatment toxicity.
• Lactate dehydrogenase (LDH): A non-specific marker elevated in cell turnover associated with aggressive malignancies.
• Circulating tumor DNA (ctDNA): Cell-free DNA shed by tumors into the bloodstream; the basis of liquid biopsy technology increasingly used alongside molecular profiling and biomarkers.

The National Cancer Institute (NCI) classifies tumor markers by intended clinical use: screening, diagnosis, prognosis, prediction of treatment response, and monitoring for recurrence (NCI, Tumor Markers).

How it works

Tumor markers reach the bloodstream through active secretion by malignant cells, passive release during cell death, or stimulated production by healthy cells reacting to tumor presence. Laboratory measurement typically uses immunoassay technology — enzyme-linked immunosorbent assay (ELISA) or electrochemiluminescence — in which antibodies bind the target molecule and quantify its concentration in nanograms per milliliter (ng/mL) or units per milliliter (U/mL).

The clinical interpretation process follows a structured sequence:

1. Baseline draw: A specimen is collected before treatment begins to establish a patient-specific reference value.
2. Threshold comparison: Results are compared against laboratory reference ranges, which are established from population studies. The College of American Pathologists (CAP) sets proficiency testing standards for tumor marker assays (CAP, Laboratory Accreditation Program).
3. Serial monitoring: Repeated measurements over time assess trends. A declining marker level during chemotherapy generally indicates treatment response; a rising level during remission may signal recurrence.
4. Correlation with imaging and biopsy: A single elevated value is not diagnostic in isolation. Per NCI guidance, markers must be interpreted alongside clinical findings, imaging for cancer, and histopathology.

Specificity and sensitivity vary substantially across markers. Prostate-specific antigen (PSA), for example, has a sensitivity of approximately 21% for prostate cancer at a threshold of 4.0 ng/mL when measured against biopsy-confirmed cases, as reported in studies reviewed by the U.S. Preventive Services Task Force (USPSTF) (USPSTF, Prostate Cancer Screening).

Common scenarios

Different tumor markers correspond to specific cancer types, though cross-reactivity and benign elevations are common. The principal markers in clinical use include:

For leukemia and lymphoma, flow cytometry and cell surface marker panels — performed on blood or bone marrow — serve as the primary diagnostic tools rather than a single serum protein. These panels identify cell lineage and aberrant antigen expression according to protocols established by the World Health Organization (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues (WHO Classification, 5th Edition).

Cancer screening guidelines from organizations including the American Cancer Society (ACS) and USPSTF specify which marker-based tests are recommended for population-level screening versus those reserved for diagnostic or monitoring purposes only. PSA testing and CA-125, for instance, are not currently recommended as routine population screening tools by USPSTF due to insufficient evidence of net benefit.

Decision boundaries

The regulatory context for oncology testing — described in detail at /regulatory-context-for-oncology — shapes which assays may be used in clinical decision-making. The FDA distinguishes between FDA-cleared assays and laboratory-developed tests (LDTs). LDTs, such as many ctDNA panels, are developed and performed within a single laboratory and have historically been regulated under Clinical Laboratory Improvement Amendments (CLIA), administered by the Centers for Medicare & Medicaid Services (CMS) (CMS, CLIA Program).

Key decision boundaries governing test interpretation:

• A single elevated marker does not confirm malignancy. Benign conditions elevate the majority of markers in routine use.
• A normal marker does not exclude malignancy. AFP is elevated in only 50–70% of hepatocellular carcinoma cases at diagnosis (NCI).
• Reference ranges are population-derived, not individually calibrated. Age, sex, race, and comorbidities affect baseline values, particularly for PSA.
• Trend matters more than absolute value. A PSA that doubles in fewer than 3 months (PSA doubling time) carries different clinical weight than a static elevation.
• Liquid biopsy results require confirmatory testing. The FDA has approved companion diagnostic ctDNA assays for specific targeted therapies, but positive findings typically prompt tissue biopsy for confirmation.

Clinicians ordering tumor marker panels are guided by the National Comprehensive Cancer Network (NCCN) guidelines, which specify marker selection, testing frequency, and threshold actions for 60+ cancer types (NCCN Clinical Practice Guidelines). Interpretation is inseparable from the broader oncology authority index, which situates these diagnostic tools within the full spectrum of oncology practice.

References

• U.S. Food and Drug Administration — In Vitro Diagnostics
• National Cancer Institute — Tumor Markers Fact Sheet
• U.S. Preventive Services Task Force — Prostate Cancer Screening Recommendation
• College of American Pathologists — Laboratory Accreditation Program
• Centers for Medicare & Medicaid Services — CLIA Program
• World Health Organization — Classification of Tumours of Haematopoietic and Lymphoid Tissues, 5th Edition
• National Comprehensive Cancer Network — Clinical Practice Guidelines in Oncology
• American Cancer Society — Cancer Screening Guidelines

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)